Lab21
has announced plans to collaboratively develop a new molecular diagnostic assay
for the detection of Aspergillus species.
The
firm has signed an agreement with a prominent but unnamed diagnostics business
to create, manufacture and distribute the product, which will be based on the
partner organisation's real-time polymerase chain reaction platform.
Molecular
diagnostic development resources will be contributed by Lab21, in addition to
intellectual property pertaining to fungal diagnostics, in order to develop the
test for use as an original equipment manufacturer reagent for the partner
platform.
The
new product will help to combat the trend of infections caused by Aspergillus,
which places an estimated ten million people at risk annually.
Graham
Mullis, chief executive officer of Lab21, said: "We are pleased to enter
into a new agreement to develop this assay. The MycAssay Aspergillus test
provides rapid, accurate clinical information that allows health professionals
to make life-saving treatment decisions quickly."
Last
month, the company announced the launch of a new clinical genomics centre
within the Greenville Hospital System Memorial Medical Campus in South
Carolina, a move that will greatly enhance Lab21's US operations.
Posted by Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources